ABIOMED, Inc.  

(Public, NASDAQ:ABMD)   Watch this stock  
Find more results for ABMD
73.03
+0.26 (0.36%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 70.75 - 74.37
52 week 58.06 - 110.68
Open 73.44
Vol / Avg. 860,870.00/757,530.00
Mkt cap 3.12B
P/E 25.77
Div/yield     -
EPS 2.83
Shares 42.44M
Beta 1.15
Inst. own 98%
May 3, 2016
Q4 2016 Abiomed Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 11, 2016
Abiomed Inc at Leerink Partners Global Healthcare Conference
Feb 4, 2016
Q3 2016 Abiomed Inc Earnings Release
Feb 4, 2016
Q3 2016 Abiomed Inc Earnings Call - Webcast
Jan 13, 2016
Abiomed Inc at JPMorgan Healthcare Conference
Jan 11, 2016
Preliminary Q3 2016 Abiomed Inc Earnings Release
Nov 19, 2015
Abiomed Inc at Jefferies Autumn Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 12.30% 49.36%
Operating margin 20.33% 12.45%
EBITD margin - 13.65%
Return on average assets 11.07% 41.81%
Return on average equity 12.51% 49.44%
Employees 589 -
CDP Score - -

Address

22 CHERRY HILL DR
DANVERS, MA 01923-2575
United States - Map
+1-978-7775410 (Phone)
+1-978-7778411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Abiomed, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company's products include Impella 2.5, a percutaneous micro heart pump with an integrated motor and sensors; Impella CP, which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD, a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000, a circulatory support system for the temporary support of acute heart failure patients in profound shock, and Symphony, a minimally invasive implantable cardiac assist device.

Officers and directors

Michael R. Minogue Chairman of the Board, President, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael Tomsicek Chief Financial Officer, Vice President, Treasurer
Age: 49
Bio & Compensation  - Reuters
David M. Weber Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
William J. Bolt Senior Vice President - Global Product Operations
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew J. Greenfield Vice President, General Manager - Global Marketing
Age: 42
Bio & Compensation  - Reuters
Michael G. Howley Vice President, General Manager - Global Sales and Marketing
Age: 51
Bio & Compensation  - Reuters
Ingrid Goldberg Director - Investor Relations
Bio & Compensation  - Reuters
Dorothy E. Puhy Lead Independent Director
Age: 64
Bio & Compensation  - Reuters
Jeannine M. Rivet Director
Age: 62
Bio & Compensation  - Reuters
Christopher D. Van Gorder Director
Bio & Compensation  - Reuters